<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692402</url>
  </required_header>
  <id_info>
    <org_study_id>DSRB 2018/00865</org_study_id>
    <nct_id>NCT04692402</nct_id>
  </id_info>
  <brief_title>Feasibility Trial Evaluating Efficacy and Safety of Solitaire™ Thrombus Retrieval Device in the Management of Refractory Thrombus in Patients With Acute Coronary Syndrome</brief_title>
  <acronym>Solitaire</acronym>
  <official_title>Feasibility Trial Evaluating Efficacy and Safety of Solitaire™ Thrombus Retrieval Device in the Management of Refractory Thrombus in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paul Ong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tan Tock Seng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a multicentre open label prospective feasibility trial to capture&#xD;
      preliminary efficacy and safety information on Solitaire device to plan an appropriate&#xD;
      pivotal study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that Solitaire device could be effectively and safely used as an adjunctive&#xD;
      interventional technique in ACS patients found to have refractory thrombus during PCI.&#xD;
&#xD;
        1. Primary Objectives To evaluate intra-procedure efficacy of using Solitaire in ACS&#xD;
           patients with refractory thrombus.&#xD;
&#xD;
        2. Secondary Objectives To evaluate clinical efficacy of using Solitaire in ACS patients&#xD;
           with refractory thrombus, up to one year post-procedure.&#xD;
&#xD;
      To evaluate safety of using Solitaire in ACS patients with refractory thrombus.&#xD;
&#xD;
      The target enrolment is 51 patients diagnosed with STEMI, NSTEMI or UA and found to have&#xD;
      refractory thrombus during PCI. Eligible patients will be identified at the ED or Inpatient&#xD;
      ward of the 5 participating hospitals. The projected enrolment period is for two years and&#xD;
      follow up for one year. A screening log will be maintained at each site to keep record of&#xD;
      patients who were eligible for the study but not enrolled, to establish any selection bias.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Investigator initiated multicentre open label prospective feasibility trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of successful recanalization defined as an immediate post-procedure Thrombolysis in Myocardial Infarction (TIMI) flow of 2 or 3.</measure>
    <time_frame>immediate post-procedure</time_frame>
    <description>Primary Efficacy Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any stroke</measure>
    <time_frame>immediate post-procedure up to 30 days</time_frame>
    <description>Occurrence of any stroke, defined as the presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours, from immediate post-procedure up to 30 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of study device-related Serious Adverse Events (SAEs) up to 30 days.</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Primary Safety Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of emboli in new territory (ENT) at 24 hrs ± 8 hrs post procedure (ENT: Embolization territories outside of the target downstream territory).</measure>
    <time_frame>at 24 hours ± 8 hours post procedure</time_frame>
    <description>Primary Safety Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of successful thrombus resolution defined as an immediate post-procedure thrombus burden of thrombus grade (TG) 1 or less</measure>
    <time_frame>immediate post-procedure</time_frame>
    <description>Secondary Endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of successful recanalization defined as a reduction in corrected TIMI frame count after use of the Solitaire device.</measure>
    <time_frame>immediate post-procedure</time_frame>
    <description>Secondary Endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of successful myocardial perfusion defined as an immediate post-procedure myocardial blush grade (MBG) of 2 or more</measure>
    <time_frame>immediate post-procedure</time_frame>
    <description>Secondary Endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of device success defined as successful delivery and retrieval of the device without complication</measure>
    <time_frame>immediate post- procedure</time_frame>
    <description>Secondary Endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of major adverse cardiac and cerebrovascular events (MACCE)</measure>
    <time_frame>up to one year post-procedure</time_frame>
    <description>Occurrence of major adverse cardiac and cerebrovascular events (MACCE), defined as composite of all cause death, myocardial infarction, target vessel revascularisation or stroke, up to one year post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality through 90 days post procedure.</measure>
    <time_frame>90 days post procedure</time_frame>
    <description>Secondary Endpoints</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Refractory Thrombus in Patients With Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open label prospective feasibility trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solitaire™ thrombus retrieval device</intervention_name>
    <description>After consent has been obtained, interventional cardiologist selects the proper solitaire device size per device-specific instructions for use. Adjunctive intervention with Solitaire will be done with a maximum of 2 device deployments. Do not perform more than three recovery attempts in the same vessel using the devices (Maximum of 2 attempts per device per subject). Do not reposition each device more than two times. TIMI flow, thrombus grade and myocardial blush grade will be assessed immediately upon completion of procedure. If recanalization is deemed inadequate by the interventional cardiologist, rescue treatment will follow as per current clinical practice. All other procedures followed will be as clinically indicated.</description>
    <arm_group_label>open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects meeting all of the inclusion criteria listed below will be included in this study:&#xD;
&#xD;
          1. Index event of ST segment elevation or non-ST segment elevation MI or Unstable Angina&#xD;
             defined as:&#xD;
&#xD;
               1. Presentation to hospital with symptoms of myocardial ischemia (Chest pain or&#xD;
                  angina equivalent) lasting for ≥10 minutes at rest&#xD;
&#xD;
                  AND 1 of the following:&#xD;
&#xD;
               2. Persistent ST segment elevation ≥1mm (0.1 mV) in two or more contiguous limb&#xD;
                  leads or ≥2mm (0.2 mV) in ) in one or more contiguous precordial leads OR&#xD;
&#xD;
               3. New or presumed new left bundle branch block (LBBB) OR&#xD;
&#xD;
               4. ST segment depression ≥1mm (0.1 mV) in two or more contiguous leads (not known to&#xD;
                  be pre-existing or due to a known cause such as LV hypertrophy or digoxin) OR&#xD;
&#xD;
               5. Troponin T or I greater than the laboratory upper normal limit.&#xD;
&#xD;
          2. Referred for urgent or emergency PCI AND Thrombus burden of TG 4 or above OR TIMI flow&#xD;
             grade of 1 or less in at least one native infarct related artery following either&#xD;
&#xD;
               1. Manual aspiration thrombectomy OR&#xD;
&#xD;
               2. Balloon Angioplasty OR&#xD;
&#xD;
               3. AngioJet RT OR&#xD;
&#xD;
               4. Patient having deferred PCI due to heavy thrombus but continue to demonstrate&#xD;
                  recalcitrant thrombus upon repeat angiography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the exclusion criteria listed below will be excluded from this&#xD;
        study:&#xD;
&#xD;
          1. Age ≤ 21 years&#xD;
&#xD;
          2. Cardiogenic shock&#xD;
&#xD;
          3. killip class 3 or above at presentation&#xD;
&#xD;
          4. Known relative contraindications for the use of Solitaire:&#xD;
&#xD;
               1. Prior stent in infarct related artery&#xD;
&#xD;
               2. Significant proximal stenosis OR Ostial lesion at angiography&#xD;
&#xD;
               3. Extensive calcification&#xD;
&#xD;
          5. Life expectancy less than six months due to non-cardiac condition&#xD;
&#xD;
          6. Participants categorised as vulnerable subjects (ex: prisoners, pregnant women, and&#xD;
             mentally disabled persons)&#xD;
&#xD;
          7. Patients at high risk of being lost to follow up (ex: non-residents)&#xD;
&#xD;
          8. Participation in any study with an investigational drug or device within the last 30&#xD;
             days&#xD;
&#xD;
          9. Patients who are unable to provide informed consent prior to any procedure .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Jau Lueng Ong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paul Ong Jau Lueng</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>cathy Haiyan li, Master Degree</last_name>
    <phone>+65 63578388</phone>
    <email>Haiyan_LI@ttsh.com.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iswarya Jayakumar, Degree</last_name>
    <phone>63578326</phone>
    <email>Iswarya_JAYAKUMAR@ttsh.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Heart Centre Singapore (NHCS)</name>
      <address>
        <city>Singapore</city>
        <state>Singaproe</state>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aishah Toh</last_name>
      <phone>(65)67042282</phone>
      <email>aishah.toh@nhcs.com.sg</email>
    </contact>
    <investigator>
      <last_name>Dr Aaron Sung Lung Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Heart Centre Singapore (NUHCS)</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolene Leong</last_name>
      <email>jolene_rachel_LEONG@nuhs.edu.sg</email>
    </contact>
    <investigator>
      <last_name>Dr Joshua LOH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital (TTSH)</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Li</last_name>
      <phone>(65)63578388</phone>
      <email>Haiyan_LI@ttsh.com.sg</email>
    </contact>
    <investigator>
      <last_name>Dr Paul Jau Lueng Ong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital (CGH) Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Li</last_name>
      <phone>(65)68502697</phone>
      <email>Li_Li@cgh.com.sg</email>
    </contact>
    <investigator>
      <last_name>Dr Yew Seong Goh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Khoo Teck Puat Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>768828</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boon Khim Lim</last_name>
      <phone>(65)66023307</phone>
      <email>lim.boon.khim@ktph.com.sg</email>
    </contact>
    <investigator>
      <last_name>Dr Syed Saqib Imran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tan Tock Seng Hospital</investigator_affiliation>
    <investigator_full_name>Paul Ong</investigator_full_name>
    <investigator_title>Consultant Cardiologist and Cathlab Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

